Gossamer Bio financials
$11.58+0.52%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $48.5M | $114.7M | $0.00 | $0.00 | $0.00 | — | — |
| Gross profit | $48.5M | $114.7M | $0.00 | $0.00 | $0.00 | — | — |
| Gross margin | 100.0% | 100.0% | — | — | — | — | — |
| Operating income | -$170.7M | -$59.9M | -$183.8M | -$218.6M | -$216.1M | -$234.0M | -$186.1M |
| Net income | -$170.4M | -$56.5M | -$179.8M | -$229.4M | -$234.0M | -$243.4M | -$180.3M |
| Net margin | −351.5% | −49.3% | — | — | — | — | — |
| Diluted EPS | $-60.00 | $-20.00 | $-94.40 | $-216.80 | $-250.40 | $-284.00 | $-263.20 |
| EBITDA | -$177.0M | -$68.8M | -$188.8M | -$216.8M | -$211.0M | -$229.7M | -$183.1M |
| Operating cash flow | -$171.3M | -$3.5M | -$159.2M | -$187.0M | -$188.9M | -$199.7M | -$148.4M |
| Free cash flow | -$171.3M | -$3.5M | -$159.2M | -$187.4M | -$190.4M | -$201.2M | -$151.4M |
| Diluted shares | 2.9M | 2.8M | 1.9M | 1.1M | 0.9M | 0.9M | 0.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $37.7M | $46.1M | $32.1M | $112.0M | $183.4M | $486.1M |
| Short-term investments | $99.2M | $248.4M | $264.3M | $143.7M | $141.8M | $26.6M |
| Total debt | $198.5M | $197.5M | $209.0M | $219.3M | $179.1M | $172.4M |
| Total assets | $172.2M | $315.3M | $311.9M | $272.4M | $343.7M | $539.4M |
| Total liabilities | $295.0M | $285.8M | $249.1M | $260.4M | $222.2M | $218.7M |
| Shareholders' equity | -$122.8M | $29.5M | $62.8M | $12.1M | $121.5M | $320.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology